ATE297752T1 - Topische mittel, die eine aminosäure in kombination mit entweder interferon oder mit thymidinderivaten enthalten, zur behandlung viraler oder entzündlicher erkrankungen - Google Patents

Topische mittel, die eine aminosäure in kombination mit entweder interferon oder mit thymidinderivaten enthalten, zur behandlung viraler oder entzündlicher erkrankungen

Info

Publication number
ATE297752T1
ATE297752T1 AT97929442T AT97929442T ATE297752T1 AT E297752 T1 ATE297752 T1 AT E297752T1 AT 97929442 T AT97929442 T AT 97929442T AT 97929442 T AT97929442 T AT 97929442T AT E297752 T1 ATE297752 T1 AT E297752T1
Authority
AT
Austria
Prior art keywords
interferon
viral
pct
thymide
derivatives
Prior art date
Application number
AT97929442T
Other languages
English (en)
Inventor
Sandor Toth
Original Assignee
Sandor Toth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandor Toth filed Critical Sandor Toth
Application granted granted Critical
Publication of ATE297752T1 publication Critical patent/ATE297752T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97929442T 1996-07-25 1997-07-03 Topische mittel, die eine aminosäure in kombination mit entweder interferon oder mit thymidinderivaten enthalten, zur behandlung viraler oder entzündlicher erkrankungen ATE297752T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9602024A HUP9602024A3 (en) 1996-07-25 1996-07-25 Pharmaceutical composition containing aminoacid for external use
PCT/HU1997/000035 WO1998004280A2 (en) 1996-07-25 1997-07-03 Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases

Publications (1)

Publication Number Publication Date
ATE297752T1 true ATE297752T1 (de) 2005-07-15

Family

ID=89994154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929442T ATE297752T1 (de) 1996-07-25 1997-07-03 Topische mittel, die eine aminosäure in kombination mit entweder interferon oder mit thymidinderivaten enthalten, zur behandlung viraler oder entzündlicher erkrankungen

Country Status (9)

Country Link
US (1) US6048843A (de)
EP (1) EP0855915B1 (de)
AT (1) ATE297752T1 (de)
AU (1) AU3354997A (de)
CA (1) CA2232710A1 (de)
DE (1) DE69733539D1 (de)
HR (1) HRP970419A2 (de)
HU (1) HUP9602024A3 (de)
WO (1) WO1998004280A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT886527E (pt) * 1996-02-28 2001-12-28 Unihart Corp Composicao farmaceutica que incorpora o interferao alfa humano natural
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
DE60021760T2 (de) 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US6415797B1 (en) * 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
EP1377291A2 (de) * 2001-03-13 2004-01-07 Protagen AG 1-butansäuderivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710376A (en) * 1985-02-01 1987-12-01 Interferon Sciences, Inc. Topical therapeutic composition containing oxidation inhibitor system
HU196038B (en) * 1987-08-07 1988-09-28 Mta Koezponti Kemiai Kutato In Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine
EP0326151B1 (de) * 1988-01-29 1993-06-16 Sumitomo Pharmaceuticals Company, Limited Verbesserte Formulierungen mit kontrollierter Abgabe
CA1339070C (en) * 1989-01-26 1997-07-29 Wulf Droge Treatment of diseases associated with cysteine deficiency

Also Published As

Publication number Publication date
HUP9602024A2 (hu) 1998-03-30
US6048843A (en) 2000-04-11
CA2232710A1 (en) 1998-02-05
HU9602024D0 (en) 1996-09-30
WO1998004280A3 (en) 1998-03-26
EP0855915B1 (de) 2005-06-15
DE69733539D1 (de) 2005-07-21
HUP9602024A3 (en) 1999-05-28
WO1998004280A2 (en) 1998-02-05
AU3354997A (en) 1998-02-20
HRP970419A2 (en) 1998-08-31
EP0855915A2 (de) 1998-08-05

Similar Documents

Publication Publication Date Title
Johnson et al. Inhibition of the primary in vitro antibody response by interferon preparations
Allen et al. Selenium sulfide: adjunctive therapy for tinea capitis
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
ATE406176T1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
LU91125I2 (fr) Ranélate den strontium et ses dérivés pharmaceutiquement acceptables (protelos).
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
ATE481135T1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
ATE297752T1 (de) Topische mittel, die eine aminosäure in kombination mit entweder interferon oder mit thymidinderivaten enthalten, zur behandlung viraler oder entzündlicher erkrankungen
CA2255681A1 (en) Composition and method for treating herpes simplex
EP0653939B1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
JPS58103324A (ja) インタ−フエロン組成物及びヘルペス感染症の治療における該組成物の使用
DE3853427D1 (de) Behandlung gealterter haut mit oraler 13-cis-retinsäure.
Jose et al. Levamisole in patients with recurrent herpes infection
Gupta et al. Keratoses in patients with psoriasis: A prospective study in fifty–two inpatients
Morris Use of vitamin C in acne vulgaris
JPH01294635A (ja) 局所投与用製薬組成物
ATE104676T1 (de) Antivirale wirkstoffe.
Verbov Eczema Herpeticum in a Man of 68
Hunter Sodium hypochlorite, an overlooked therapeutic adjunct for Herpes simplex infections
RU97115801A (ru) Способ лечения стенозирующих ларинготрахеитов у детей
RU93032703A (ru) Способ лечения острых респираторных заболеваний
BG97498U (bg) Средство за лечение на хемороиди и кожни заболявания

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties